The new coronavirus mRNA vaccine independently developed by RiboBio and Agna Biopharmaceuticals has started clinical trials

On January 10, 2022, the Phase I clinical trial of mRNA vaccine for the prevention of novel coronavirus pneumonia was officially launched in Chengdu

Vaccination is one of the most effective public health interventions to prevent and control infectious diseases

With the support of the government's new crown emergency research project, Ribo Bio, Agna Biopharmaceutical, the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences and the Guangzhou National Laboratory carried out scientific research cooperation, and jointly carried out the mRNA of the original strain and variant strain of the new coronavirus Vaccine development and production

RiboBio is China's leading nucleic acid technology benchmarking enterprise and a key high-tech enterprise of the National Torch Program.

Agna Biopharmaceuticals is a biopharmaceutical company founded by the world's top scientists.